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A Renin-ssance in Primary Aldosteronism Testing:
Obstacles and Opportunities for Screening, Diagnosis,
and Management
Moderators: Joshua E. Raizman1 and Eleftherios P. Diamandis1,2,3*
Experts: Daniel Holmes,4,5 Michael Stowasser,6 Richard Auchus,7 and Etienne Cavalier8
Primary aldosteronism (PA)9 is a group of adrenal disor-
ders characterized by autonomous production of aldoste-
rone independent of angiotensin II (AngII) stimulation.
Idiopathic adrenal hyperplasia is the most common cause
followed by aldosterone-producing adenomas (APA or
Conn syndrome), unilateral adrenal hyperplasia, adrenal
carcinoma, and rare familial forms. Aldosterone excess
results in sodium and water retention and potassium ex-
cretion, leading to volume expansion, concomitant hy-
pertension, and variable degrees of hypokalemia. As the
most common form of secondary hypertension, PA is
recognized as an important public health concern. The
diagnosis is infrequently considered despite widely avail-
able screening procedures. In addition to the hyperten-
sion, the negative effects of excess aldosterone are
thought to be related to inflammation and fibrosis of
various target organs. As a result, patients with PA are at
increased risk of cardiovascular and chronic kidney dis-
ease compared with age-matched and blood pressure–
matched patients with essential hypertension. For these
reasons early identification and treatment are necessary to
prevent morbidity andmortality associated with this cur-
able form of chronic hypertension.
The diagnosis of PA relies on biochemical evidence of
relative aldosterone excess and confirmation of abnormal
aldosterone production using suppression testing. The
identification of the PA subtype is primarily accom-
plished with adrenal venous sampling and imaging stud-
ies. The aldosterone-to-renin ratio (ARR) is generally
considered the best first-line screening test for hyperten-
sive patients in whom there is clinical suspicion of PA.
Excessive and autonomous aldosterone secretion is char-
acteristically accompanied by low or undetectable renin
due to feedback inhibition from sodium excess and in-
creased blood pressure. However, no consensus exists for
an internationally recognized ARR cutoff andmany chal-
lenges, from preanalytical to analytical to postanalytical,
have hindered the development of definitive guidance on
how to interpret the ARR in clinical practice.
In thisQ&A, 4 experts from around the world discuss the
state-of-the-art in screening and diagnosis of PA and the
many challenges associated with laboratory testing.
Estimates of prevalence suggest that PA is more com-
mon than once thought. What is known about the
current prevalence, and why do you think historical
estimates were misleading? Are certain populations at
increased risk?
Daniel Holmes: The
largest studies have consis-
tently determined the
prevalence to lie between
5% and 15% in hyperten-
sive populations. Histori-
cal estimates were mis-
leading because it was
assumed that hypokale-
mia was a sine qua non of
the diagnosis. However,
about half of patients with
APA, and only 17% of those with idiopathic adrenal
hyperplasia, are hypokalemic. The other contributing
factor may be that many patients with PA do not have
increases of aldosterone above the reference interval.
Rather, they have increases relative to AngII stimulation,
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the surrogate measure of which is plasma renin activity
(PRA). The Endocrine Society Guideline, in the US,
recommends a targeted screening approach in subpopu-
lations with hypertension having clinical features sugges-
tive of PA, which are: 1) those with moderate to severe or
resistant hypertension; 2) hypertension with spontane-
ous or diuretic-induced hypokalemia; 3) hypertension
presenting with an adrenal incidentaloma; and 4) hyper-
tension in the context of a family history of hypertension
or early cerebrovascular accident. There is also evidence
that PA is more likely to be found among those with
obesity, diabetes, and obstructive sleep apnea.
Michael Stowasser:
Throughout the 1970s to
early 1990s, PA was con-




kalemic. The two main
factors that led to the
demonstration that PA
was much more common
were: 1) the introduction
of the ARR as a screening test, which proved to be more
sensitive than aldosterone assessed separately with renin,
and 2) the application of the ARR to a wider population
to include normokalemic patients and those with milder
forms of hypertension. Estimates of prevalence among
all-comer hypertensive patients in most recent studies
have been 5%–13%. Although PA is undoubtedly more
common among hypokalemic hypertensive patients, this
group represents only the “tip of the iceberg” (approxi-
mately 20% of patients), and only selecting this popula-
tion for screening will miss most of the other patients
with this condition. Other populations that appear to be
at increased risk include hypertensive patients with ob-
structive sleep apnea, diabetic patients, and those with
incidentally discovered adrenal lesions. A strong argu-
ment can also be made for early screening in all hyper-
tensive patients. This claim is based on the fact that 1) PA
is highly prevalent among hypertensive patients, 2) the
ARR test is reasonably inexpensive, 3) surgical outcomes
are better than nonspecific antihypertensive treatment,
4) early detection improves those outcomes, and 5) the
ARR is most reliable if measured before patients go on
antihypertensives.
Richard Auchus: This is a trick question, because it de-
pends on how PA is defined, particularly when not
caused by an adrenal tumor. If strict criteria are used,
such as a 24-h urine aldosterone 14 g/day (38.8
nmol/day) during the salt-loading confirmatory test or
serum aldosterone 10 ng/dL (277 pmol/L, using
older RIA assays) after the saline infusion test, then the
prevalence among hypertensive patients is approximately
5%–8%. The prevalence is up to 20% among those with
resistant hypertension. Development of PA is a gradual
process, and it is quite likely that lower amounts of au-
tonomous aldosterone production can contribute to low-
renin hypertension in some healthy individuals, depend-
ing on their genetic makeup and the sodium content of
their diet.
The ARR is established as the best front-line test to
screen for PA. What makes the ARR superior to
testing either serum aldosterone or renin separately?
Daniel Holmes:When we think about endocrine disor-
ders caused by autonomous hormone production, we of-
ten think of the end hormone concentration as being
high-normal or overtly high while the stimulating hor-
mone is low or undetectable. Graves disease is a good
example of this: thyroxine is often overtly high and
thyroid-stimulating hormone is low or undetectable. In
the case of PA, this is often not the case. There are 2
reasons for this. First, the potassium wasting that fre-
quently occurs with PA causes hypokalemia or low-
normal potassium concentrations, which decreases aldo-
sterone production. Second, patients are often receiving
antihypertensives that lower aldosterone—specifically,
angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers,  blockers, and dihydropyridine cal-
cium channel blockers. For this reason, aldosterone in
isolation is not a very useful tool, since plasma concen-
trations are often well within the normal range and some-
times as low as 9 ng/dL (250 pmol/L) even in the absence
of hypokalemia and antihypertensive use. Renin alone is
not specific because it would fail to distinguish PA from
other forms of low-renin hypertension such as severe
Cushing syndrome, Liddle syndrome, and the hyperten-
sive forms of congenital adrenal hyperplasia.
Michael Stowasser: Isolated measurement of plasma al-
dosterone lacks sensitivity for PA, since many patients
exhibit concentrations that are within the wide normal
range, even those with unilateral APA. Such “normal”
concentrations could be viewed as “inappropriately nor-
mal” in the face of suppression of the renin-angiotensin-
aldosterone system. While highly sensitive for PA, sup-
pressed renin concentrations lack specificity. Suppressed
renin can occur in treatment with -blocking agents,
clonidine, -methyldopa, or nonsteroidal antiinflamma-
tory agents, or with consumption of a high-salt diet, ad-
vancing age, chronic renal impairment, and a large list of
other salt-dependent and low-renin forms of hyperten-
sion. In contrast to PA, aldosterone concentrations in
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low-renin hypertension are chronically suppressed as a
result of chronic suppression of renin/AngII.
Richard Auchus:Renin is
critical for screening be-
cause the diagnosis can
only be made when renin
is below the normal range
or undetectable. When
renin is normal, aldoste-
rone production can be
considered physiologic. If
renin is low, then any ex-
cess aldosterone is abnor-
mal; the higher the serum
aldosterone, the more likely the patient has PA. In fact, I
never calculate an absolute ARR. I always interpret the 2
tests separately, especially in the context of serum potas-
sium. This is because hypokalemia suppresses aldoste-
rone production and often leads to falsely low serum
aldosterone and, in turn, false-negative screens.
There is considerable variability in cutoff values for
the ARR. What has contributed to such variability?
How could serum aldosterone thresholds be used to
help improve interpretation of the ARR?
Etienne Cavalier: This
variability is the conse-




ries. The ratio combines 2
analytical errors, which
could confound the inter-
pretation of the ARR.
Furthermore, a cutoff
value relies on the specific
methods that were used to establish it, and, unfortu-
nately, cutoff values are often derived without consider-
ation of the effect of analytical methodologies and stan-
dardization. Until recently, aldosterone measurement
was achieved via cumbersome RIA methods. Since then,
automated immunoassays and LC-MS/MS methods
have become available. While LC-MS/MS is undoubt-
edly more specific than immunoassay, a higher-order ref-
erence method as well as an International Standard Ref-
erence Material for aldosterone is still needed.
Michael Stowasser: Disparity between laboratory ap-
proaches is a major issue, with for example, some groups
retaining RIAs for determining PRA, while many others
are moving to LC-MS/MS or other automated immuno-
metric methods of measuring direct renin concentration
(DRC) using mass assays. The reporting of both aldoste-
rone and renin in different units between laboratories has
added to the complexity. Hopefully, this problem will
diminish with time as more laboratories adopt the Sys-
te`me Internationale method of reporting aldosterone
concentrations (as pmol/L), follow more uniform ap-
proaches to screening that are now widely circulated in
published reviews and guidelines, and change to more
reliable assay methodology. It has been shown that in the
presence of extremely low renin concentrations (i.e., PRA
0.1 ng/mL  h or DRC 2 mU/L), the ARR may be
increased even when plasma aldosterone is also very low
(i.e., 110 pmol/L or 4 ng/dL) and clearly not consistent
with PA. Some investigators have therefore suggested the
inclusion of a minimum plasma aldosterone concentra-
tion of 15 ng/dL (415 pmol/L) within the screening cri-
teria, but this approach would miss many cases because
plasma aldosterone concentrations often fall below this
cutoff. For this reason, our approach is to proceed with
diagnostic workup for PA in all patients with increased
ARR, except in those whose plasma aldosterone concen-
tration is below the level used to define normal suppres-
sion during confirmatory fludrocortisone suppression
testing (6 ng/dL or 165 pmol/L). In those patients, we
will periodically repeat the ARR and consider further
diagnostic workup.
Daniel Holmes: Published ARR screening thresholds
vary up to 10-fold. While the variability in the ARR is
attributable in part to cohort selection, screening proto-
cols, confirmatory testing, and disease definition, the
most underappreciated problem in clinical studies is an
analytical one—both for aldosterone and renin. Consid-
ering renin in isolation, PRA results are affected by assay
design (incubation time or buffering pH) and the analyt-
ical components (choice of antibody, analytical method-
ology, and calibrator). DRC assays have challenges, par-
ticularly in the low-renin state, due to both poor
precision and correlation with the more established PRA.
Cross-reactivity of DRC with catalytically active confor-
mations of prorenin is also a concern because the concen-
tration of prorenin, which is normally 10-fold higher
than renin, goes up to 100-fold higher in low-renin states
such as PA. Regarding aldosterone cutoff values, about
one third of PA cases may have ambulatory aldosterone
concentrations15 ng/dL (415 pmol/L). Therefore, it is
prudent to avoid definitive statements about the exact
concentration below which PA will never be observed
and to always interpret a result with clinical presentation
in mind.
Richard Auchus: That is why I never calculate an ARR!
At an ARR of 20 ng/dL:ng/mL  h (550 pmol/L:ng/
mL  h using PRA) the sensitivity and specificity are both
approximately 80%. As the cutoff value is set higher, the
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specificity improves little, but the sensitivity plummets.
My approach is to interpret renin and aldosterone sepa-
rately. If renin is low (1 ng/mL  h) and aldosterone
relatively high [10 ng/dL (277 pmol/L)], I proceed to
confirmatory testing. In fact, I will do confirmatory test-
ing if aldosterone is 5–10 ng/dL (139–277 pmol/L) and
my index of suspicion is high, such as in a young patient
with hypokalemia. It is important to realize that these
cutoff values are set for patients on no medications.
When a patient is taking vasodilators and diuretics, a
nonsuppressed PRA (i.e., 2–3 ng/mL  h) with an aldo-
sterone 20 ng/dL (550 pmol/L) is highly suspicious
and warrants rescreening after withdrawing them.
There are many preanalytical and analytical chal-
lenges to the measurement of aldosterone and renin.
Briefly discuss which interferences you think are most
important to consider, and what approaches should
be used to minimize inaccurate results.
Michael Stowasser:Themajor controllable confounders
are posture, time of day, dietary sodium intake, plasma
potassium, and medications, which all impact the renin
angiotensin aldosterone system. Medications causing
false positives include -blockers, clonidine, methyl-
dopa, and nonsteroidal antiinflammatory drugs. False
negatives can occur with angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, diuretics, and
dihydropyridine calcium blockers. Selective serotonin re-
uptake inhibitors lower the ARR, with the potential for
false negatives. Renin inhibitors lower PRA but raise
DRC, and so their effect on the ARR is method depen-
dent. ARR values are higher in premenopausal women
than in age-matched males, especially during the luteal
phase of the menstrual cycle when false positives can
occur if renin is measured by DRC (but not PRA).
Estrogen-containing oral contraceptive agents may cause
false-positive ARRs with DRC assays (rather than PRA).
False positives can also occur in patients of advanced age
and in patients with chronic kidney disease. Tominimize
inaccurate results, patients should be encouraged to lib-
eralize sodium intake. Medications that significantly af-
fect the ARR should be withdrawn at least 4 weeks for
both potassium-sparing and potassium-wasting diuret-
ics, and at least 2 weeks for other potentially interfering
drugs. Where necessary to maintain hypertension con-
trol, other antihypertensive medications that have less
significant effects on the ARR ( blockers or nondihy-
dropyridine calcium channel blocker) are recommended.
Blood collection timing is important and should be un-
dertaken midmorning after the patient has been ambu-
lant for at least 2 h and seated for 5–15 min.
Daniel Holmes: Aldosterone results produced by differ-
ent immunoassays can vary 2-fold on the same samples.
The origins of this bias are multifactorial. First, there is
no international standardized reference material for aldo-
sterone, meaning that all assays, whether commercial or
lab developed, rely on gravimetric assignment. Second,
though homogenous RIAs and automated homogenous
chemiluminescent immunoassays have greatly simplified
the analysis, they have introduced a problem of metabo-
lite cross-reactivity previously mitigated by extraction
steps. We have observed this to be particularly marked in
the context of chronic renal impairment, where I would
recommend that homogenous immunoassays for aldoste-
rone not be used at all in favor of more specific LC-
MS/MS methods. Furthermore, both PRA and DRC
assays are vulnerable to spurious increases from prorenin
cryoactivation. About 2% of prorenin is catalytically ac-
tive but this fraction can be increased by the spontaneous
and reversible unfolding of the prosegment, which ex-
poses the active site and causes consumption of endoge-
nous angiotensinogen leading to overestimation of renin
activity and concentration. The unfolding of the proseg-
ment is facilitated by refrigeration but can also occur at
room temperature. We recommend rapid separation of
EDTA plasma from cells, immediate freezing and storage
at 20 °C, and rapid thawing at the time of analysis.
PRA and DRC (mass assays) are both widely used
methods for renin determination. In your opinion,
what factors should laboratories consider when de-
ciding which method to implement? Are there situa-
tions where one renin method would be better suited
than the other?
Daniel Holmes: Unfortunately, the decision to imple-
ment PRA vs DRC is often not a matter of choice for
laboratorians and the endocrinologists/internists they
serve. My experience is that the availability of suitable
instrumentation has more bearing than do the prefer-
ences of interested parties. That being said, if there is a
choice, PRA offers a long-established body of supporting
literature, better low-end analytical sensitivity with lon-
ger incubation times, and the option to use LC-MS/MS
requiring no proprietary reagents. However, PRA ismore
time-consuming and technically challenging.
Michael Stowasser:Concerns have been raised about the
faster, more convenient methods of DRC using immu-
nometric techniques and automated machinery, which
have widely been adopted in large, busy laboratories in
recent years. These include unreliability and poor repro-
ducibility, particular at the low end of the reference
range, which is particularly relevant to PA. Unlike PRA,
DRC assays do not take into account circulating concen-
trations of endogenous substrate and are therefore af-
fected by factors such as endogenous or exogenously ad-
ministered estrogen. This has been demonstrated to
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cause false-positive ARRs among women in the luteal
phase of the menstrual cycle and in those receiving
estrogen-containing oral contraceptives. For the PRA as-
say, analytical sensitivity can be improved by increasing
the duration of the incubation step during which angio-
tensin I is generated (and directly measured) from cleav-
age of endogenous angiotensinogen by renin.
Etienne Cavalier: DRC and PRA assays provide differ-
ent, but complementary, clinical information. Unspe-
cialized laboratories should use immunoassays because,
on the one hand, screening for PA must be available
everywhere and, on the other hand, using immunoassays
will help reduce lab-to-laboratory variability and improve
turnaround times. PRA should be regarded as the refer-
ence method (preferably by LC-MS/MS) for renin
measurement.
Richard Auchus: PRA is the gold standard method, but
DRC has several advantages, primarily speed and auto-
mation. In the US, the DRC assay is not widely available.
One challenge of the DRC method is that it is unclear
where to set the cutoff for a “low” renin value. It is also
well known that DRC is more vulnerable to false in-
creases from estrogen therapy and renin inhibitor medi-
cations such as aliskerin.
In the US, the Endocrine Society guidelines recom-
mend that a positive ARR test should be followed up
with 1 of 4 confirmatory tests: oral sodium loading,
saline infusion (SST), fludrocortisone suppression
(FST), or the captopril test. Which one is superior
and what factors dictate the choice of one over the
others? What tests are used to determine candidates
for surgery?
Daniel Holmes: The gold standard for the diagnosis of
PA is the reversal of symptoms after therapeutic interven-
tion: surgery for APA or administrate of mineralocorti-
coid receptor antagonist for bilateral IHA. For this reason
“confirmatory” testing is not diagnostic in the strictest
sense. Each test has advantages and disadvantages and it
would be difficult to definitively assign one as best in all
circumstances. Ultimately, it comes down to issues of
safety and convenience vs test performance characteris-
tics and available literature support. Our largest body of
experience is with the SST and we have become comfort-
able with its strengths and weaknesses in the context of
LC-MS/MS aldosterone analysis. But, the simplest test is
the one you do not need to do at all, so it is worth
mentioning that if the clinical presentation and screening
biochemistry is pathognomonic of PA (e.g., hyperten-
sion, hypokalemia, aldosterone above the reference inter-
val, and undetectable PRA), it is clinically reasonable to
omit confirmatory testing and proceed to adrenal venous
sampling for assessment of lateralization in patients who
are potential surgical candidates.
Michael Stowasser: We have found FST to be most
sensitive and accurate but it requires hospital admission,
is difficult to perform, and is relatively expensive. SST has
the advantage of requiring only a brief outpatient visit.
However, we have previously found recumbent SST to
lack sensitivity, with many patients being missed because
aldosterone concentrations are lower in the recumbent
position. In a recently published pilot study, we showed
that upright SST (performed in the seated position) cor-
rectly identified 23 of 24 patients with PA, while recum-
bent SST was positive in only 8. The oral sodium–
loading suppression test, favored by the Mayo Clinic,
appeared to bemore sensitive than recumbent STTwhen
we tested a modified version of it against FST. However,
it has the potential to suffer from the usual issues related
to obtaining accurate 24-h urine collections and the de-
gree to which the measured aldosterone concentration
truly reflects the rate of aldosterone synthesis due to
cross-reactivity to conjugated forms found in urine. The
captopril challenge test, while relatively convenient and
easy to perform, is not as well validated and has been
reported to be associated with a significant number of
false positives and negatives.
Etienne Cavalier: The most reliable means of differen-
tiating unilateral (curable by adrenalectomy) from bilat-
eral (treatedmedically with drugs that reduce aldosterone
activity) forms of PA is adrenal venous sampling of aldo-
sterone and cortisol. Technical oversight is required to
ensure correct sample labeling. A laboratory technologist
should be present during the entire process. It is impor-
tant to be aware that aldosterone and cortisol values may
be very high, thus requiring multiple dilutions, which
may lead to matrix effects.
What are the major developments in our understand-
ing of the genetic basis for PA, and how might this
hold promise toward improvements in diagnosis and
therapy?
Etienne Cavalier: Familial PA type 1 (or glucocorticoid
remediable PA), is the consequence of a chimeric gene
occurring from an irregular crossover during meiosis
causing expression of aldosterone synthase in response to
adrenocorticotropic hormone (ACTH). Patients with
this disease show severe hypertension and hemorrhagic
stroke events at a young age. Treatment consists of glu-
cocorticoid administration. Familial PA type 2 is charac-
terized by various presentations among the same pedigree
APA or hyperplasia. Although its transmission is auto-
somal dominant, no genes have been identified to date.
Treatment of this subtype does not differ from classical
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PA. The recent discovery amutation in a gene [potassium
inwardly-rectifying channel subfamily J member 5
(KCNJ5)10] coding for GIRK4, a potassium channel was
shown to cause familial PA type 3. As a result, cellular
membrane depolarization leads to aldosterone produc-
tion, excretion and cellular growth, hyperplasia, and
adenoma. In these cases, hypertension is severe with
profound hypokalemia. Bilateral adrenalectomy is fre-
quently necessary to control hypertension.
Richard Auchus: The identification of KCNJ5 muta-
tions in familial PA type 3 and in a high fraction of
APAs is probably the most significant advance in the
field in over a decade. This work then led to the
discovery of various plasma membrane channel
mutations [sodium/potassium-transporting ATPase
subunit alpha-1 (ATP1A1), plasma membrane
calcium-transporting ATPase 3 (ATP2B3), and
voltage-dependent calcium channel type L alpha 1D sub-
unit (CACNA1D)] in other APAs. These findings pro-
vide insight into the pathogenesis of idiopathic (bilateral)
hyperaldosteronism, indicate the inherent heterogeneity
of these tumors, and help identify potential therapeutic
targets formedical management of PA. Several important
questions remain unanswered. Are the molecular mech-
anisms of aldosterone production and tumor formation
the same, different, or partially overlapping? Are these
driver mutations sufficient to cause PA? Is there a preclin-
ical state that can be detected early and treated to prevent
the evolution to PA? We are likely to see many exciting
developments along these lines in the next decade.
Michael Stowasser: The identification of these KCNJ5,
ATP1A1, ATP2B3, and CACNA1D mutations has
greatly enhanced knowledge regarding the roles of these
channels in adrenal physiology and pathophysiology and
has the potential to lead to new diagnostic and therapeu-
tic strategies. However, the argument against genetic test-
ing as a clinical tool is that these mutations are almost
always somatic and only very rarely associated with the
familial occurrence of PA. Their detection in removed
tumors does not yet have obvious implications for differ-
ential management of patients with APA. This could
change as more is discovered about those factors which
predispose patients to somatic mutations and their asso-
ciated phenotype.
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